- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | OKYO Pharma beruft Expertengremium zu Medikamentenkandidat Urcosimod ein | 3 | Investing.com Deutsch | ||
| Di | OKYO Pharma plant Expertentreffen zu Urcosimod auf ASCRS-Jahrestagung | 1 | Investing.com Deutsch | ||
| Di | OKYO Pharma to hold advisory board meeting at ASCRS conference | 1 | Investing.com | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting | 248 | GlobeNewswire (Europe) | LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| Di | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.03. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 306 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Director Acquires Shares | 367 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Chief Development Officer and Director Acquires Shares | 402 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 18.03. | OKYO Pharma reports quality of life improvements in pain trial | 2 | Investing.com | ||
| 18.03. | OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain | 338 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.03. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.02. | OKYO Pharma LTD: OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress | 278 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.02. | Piper Sandler startet Coverage für OKYO Pharma mit 'Overweight'-Rating | 3 | Investing.com Deutsch | ||
| 20.02. | Piper Sandler initiates OKYO Pharma stock with Overweight rating | 2 | Investing.com | ||
| 13.02. | OKYO Pharma kündigt Aktienplatzierung im Wert von 20 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 13.02. | OKYO Pharma prices public offering at $1.85/share to raise up to $20M | 3 | Seeking Alpha | ||
| 13.02. | OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares | 464 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.02. | OKYO Pharma launches underwritten public offering of ordinary shares | 1 | Seeking Alpha | ||
| 12.02. | OKYO Pharma Announces Public Offering of Ordinary Shares | 379 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 508,20 | 0,00 % | IDEXX Laboratories, Inc.: IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma | Helping clinicians investigate sooner and plan next steps with confidence IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the availability... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,334 | -0,48 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,938 | -0,85 % | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,008 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,621 | +0,42 % | ANAVEX LIFE SCIENCES CORP in ruhiger Marktphase | ||
| CELLAVISION | 14,000 | 0,00 % | CellaVision: Solid Quarter driven by Strong Performance in Americas | Organic sales growth:Q4, 2025: 12.2% (-7.4)EBITDA margin:Q4, 2025: 33% (33)Oktober 1st - December 31st, 2025Net sales increased by 5.6% (-7.0) to SEK 197 m (187).Sales increased organically by 12.2%... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 5,250 | +2,54 % | Precision BioSciences: Sind das jetzt Super-Schnäppchen? | Die Aktie von Precision BioSciences ist eines der wenigen Biotech-Papiere, die in diesem Jahr keinen Höhenflug erlebten. Im Gegenteil: Die Aktie hat ohne schlechte Unternehmensnews in den letzten Monaten... ► Artikel lesen | |
| ZYMEWORKS | 22,600 | -0,18 % | Zymeworks Inc.: Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth | • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq:... ► Artikel lesen | |
| VTV THERAPEUTICS | 32,200 | -1,23 % | vTv Therapeutics Inc.: vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| QUOIN PHARMACEUTICALS | 4,940 | 0,00 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | - Closes Private Placement Financing of Up to $104.5 Million - Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe - Advances Proposed Expedited Regulatory... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,600 | -1,29 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,097 | -5,59 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results | PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 0,869 | -1,14 % | MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies | Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain MIAMI, FL / ACCESS... ► Artikel lesen | |
| NUVATION BIO | 4,560 | +0,44 % | Nuvation Bio stock rating reaffirmed at Buy by Truist Securities | ||
| ONCONETIX | 2,580 | +130,36 % | Onconetix, Inc.: Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,62 % bei einem Aktienkurs von 1,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.